Stephane Piat

About Stephane Piat

Stéphane Piat is a French executive with deep expertise in medical devices, particularly in cardiology and cardiovascular technologies. He joined CARMAT in September 2016 as Chief Executive Officer and later became a member of the Board of Directors on 24 April 2017. His profile reflects a long international career in major medtech companies, combining commercial development, market expansion, clinical launch management and strategic leadership in highly regulated healthcare environments. He began his career in 1995 at Becton Dickinson European Headquarters as a market researcher, before being appointed European Platform Leader for Locoregional Anaesthesia. In 2002, he joined Cordis, a Johnson & Johnson company, where he held several management roles ranging from Business Director France to European Marketing Director for Cardiology. These positions gave him broad exposure to market development, sales management and portfolio strategy across different European markets. In 2007, Piat moved to Abbott Vascular Mid-Size Europe as General Manager. Two years later, he became General Manager for the EMEA region at Evalve, where he was responsible for the clinical and commercial development of Mitraclip, a major interventional cardiology product. In 2014, he joined Abbott Vascular’s Structural Heart division in San Francisco as Division Vice President, Global Market Development. This step marked an important stage in his career, strengthening his experience in global market access and the scaling of innovative cardiac therapies. At CARMAT, Stéphane Piat has been a key executive during the company’s industrial and commercial ramp-up for Aeson®, the total artificial heart developed by the French listed company. His appointment was presented by CARMAT as the arrival of a recognized specialist with the leadership and industry knowledge needed to support the company’s next phase of growth. His expertise covers commercial strategy, product launch execution, international market development, and the alignment of clinical, regulatory and operational priorities. He holds a Master’s degree in Management Science from IAE Dijon School of Management and a postgraduate degree in Quantitative Marketing from ESA business school in Grenoble. Overall, he stands out as a medtech leader with a strong track record of bringing complex cardiovascular innovations closer to market adoption.